Document is current
Any future updates will be listed below
-
Authors
Kumar, Dhiraj https://orcid.org/0000-0002-6085-5911
Gurrapu, Sreeharsha
Wang, Yan
Bae, Seong-Yeon https://orcid.org/0000-0002-4680-5301
Pandey, Poonam R.
Chen, Hong
Mondal, Jayanta
Han, Hyunho https://orcid.org/0000-0002-6268-0860
Wu, Chang-Jiun https://orcid.org/0000-0001-8350-6397
Karaiskos, Spyros
Yang, Fei
Sahin, Aysegul
Wistuba, Ignacio I.
Gao, Jianjun https://orcid.org/0000-0001-6138-4472
Tripathy, Debasish https://orcid.org/0000-0002-5711-2404
Gao, Hua https://orcid.org/0000-0002-9698-5830
Izar, Benjamin https://orcid.org/0000-0003-2379-6702
Giancotti, Filippo G. https://orcid.org/0000-0002-0541-9519
- License Information
-
More Information
Article History
Received: 2 August 2022
Accepted: 22 November 2023
First Online: 9 January 2024
Competing interests
: B.I. is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca and Merck and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore and Synthekine. The other authors declare no competing interests.
